Key facts
- Johnson & Johnson's Erleada drug, used with hormone therapy, showed significant improvements in a late-stage prostate cancer study.
- The regimen reduced the risk of cancer spread or death by 20%.
- Patients on the regimen were nine times more likely to have little to no detectable cancer at surgery.
- Study data was presented at the American Society of Clinical Oncology meeting.
The study results for Johnson & Johnson's Erleada offer potential new treatment options for prostate cancer patients, particularly those undergoing surgery. Improved cancer elimination and reduced risk of progression or death are key metrics for evaluating the efficacy of cancer therapies. The findings presented at a major oncology conference could influence future treatment protocols and drug pricing discussions.